Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

被引：2

作者：

Tournilhac, Olivier ^{[1
]}

Lecolant, Solene ^{[2
]}

Hacini, Maya ^{[3
]}

Bouabdallah, Krimo ^{[4
]}

Bailly, Sebastien ^{[5
]}

Laribi, Kamel ^{[6
]}

Belmondo, Thibaut ^{[7
,8
,9
]}

Maerevoet, Marie ^{[10
]}

Ysebaert, Loic ^{[11
]}

Guidez, Stephanie ^{[12
]}

Le Gouill, Steven ^{[13
]}

Bonnet, Christophe ^{[14
]}

Andre, Marc ^{[15
]}

Dupuis, Jehan ^{[16
]}

Thieblemont, Catherine ^{[17
]}

Bachy, Emmanuel ^{[18
]}

Daguindau, Nicolas ^{[19
]}

Morschhauser, Franck ^{[20
,21
,22
]}

Tricot, Sabine ^{[23
]}

Feugier, Pierre ^{[24
]}

Banos, Anne ^{[25
]}

Lamy, Thierry ^{[26
]}

Chauchet, Adrien ^{[27
]}

Gyan, Emmanuel ^{[28
]}

Cartron, Guillaume ^{[29
]}

Farhat, Hassan ^{[30
]}

Camus, Vincent ^{[31
]}

Drenou, Bernard ^{[32
]}

Zerazhi, Hacene ^{[33
]}

Sibon, David ^{[34
]}

Nicolas-Virelizier, Emmanuelle ^{[35
]}

Delette, Caroline ^{[36
]}

Snauwaert, Sylvia ^{[37
]}

Straetmans, Nicole ^{[38
]}

Delarue, Richard ^{[39
]}

Parrens, Marie ^{[40
]}

Griolet, Samuel ^{[41
]}

Gaulard, Philippe ^{[42
]}

Delfau-Larue, Marie-Helene ^{[43
]}

De Leval, Laurence ^{[44
,45
]}

Damaj, Gandhi Laurent ^{[46
]}

机构：

[1] Univ Clermont Auvergne, CHU, Serv Hematol Clin & Therapie Cellulaire, EA7453 Chelter CIC 1405, Clermont Ferrand, France

[2] Grp Hosp Henri Mondor, AP HP, Dept Biol Hematol & Immunol, Lab Immunol, Creteil, France

[3] Ctr Hosp Metropole Savoie, Hematol, Chambery, France

[4] CHU Bordeaux, Hematol & Cellular Therapy Dept, Pessac, France

[5] CHU Clermont Ferrand, Hematol & Therapie Cellulaire, Clermont Ferrand, France

[6] CH Le Mans, Hematol Clin, Le Mans, France

[7] Grp Hosp Henri Mondor, Dept Biol Hematol & Immunol, Creteil, France

[8] Grp Hosp Henri Mondor, Lab Immunol, Creteil, France

[9] Grp Hosp Henri Mondor, AP HP, Creteil, France

[10] ULB, Inst Jules Bordet, Hematol, Brussels, Belgium

[11] IUCT Oncopole, Toulouse, France

[12] CHU Poitiers, Serv Hematol & Therapie Cellulaire, CIC INSERM 1402, Poitiers, France

[13] Inst Curie Comprehens Canc Ctr, Paris, France

[14] CHU Univ Liege, Clin Hematol, Liege, Belgium

[15] Catholic Univ Louvain, Dept Hematol, CHU UCL Namur, Yvoir, Belgium

[16] Henri Mondor Univ Hosp, Lymphoid Malignancies Dept, Creteil, France

[17] Univ Paris Cite, St Louis Univ Hosp, AP HP, Hematooncol Dept, Paris, France

[18] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[19] CH Annecy Genevois, Hematol Dept, Annecy, France

[20] CHU Lille, Serv Malad Sang, F-59000 Lille, France

[21] Univ Lille 2, Ctr Hosp Reg Univ CHRU Lille, Dept Clin Hematol, Lille, France

[22] Univ Lille 2, Unite Grp Rech Formes Injetables & Technol Associ, Lille, France

[23] CH Valenciennes, Serv Hematol Clin, Valenciennes, France

[24] Henri Poincare Univ, Dept Hematol, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France

[25] Ctr Hosp Bayonne, Serv Hematol, Bayonne, France

[26] CHU Rennes, Serv Hematol Clin, Rennes, France

[27] CHU Besancon, Hematol, Besancon, France

[28] CHU Tours, Serv Hematol & Therapie Cellulaire, Tours, France

[29] CHU Montpellier, Dept Hematol Clin, Montpellier, France

[30] Hop Andre Mignot, Dept Hematol, Ctr Hosp Versailles, Le Chesnay, France

[31] Ctr Henri Becquerel, Dept Clin Hematol, Rouen, France

[32] Grp Hosp Reg Mulhouse Sud Alsace GHRMSA, Serv Hematol, Mulhouse, France

[33] CH Avignon, Hematol, Avignon, France

[34] Paris Est Creteil Univ, Fac Med & Hlth, Campus Henri Mondor, Creteil, France

[35] Ctr Leon Berard, Hematol, Lyon, France

[36] CHU Amiens, Serv Hematol Clin & Therapie Cellulaire, Amiens, France

[37] Acad Hosp St Jan, Brugge, Belgium

[38] Clin Univ St Luc, Dept Hematol, Woluwe St Lambert, Belgium

[39] Necker Univ Hosp, AP HP, Hematol Dept, Hemophilia Ctr, Paris, France

[40] Univ Bordeaux, Dept Pathol, Bordeaux, France

[41] Ctr Hosp Lyon Sud, Lymphoma Acad Res Org LYSARC, Lyon, France

[42] Henri Mondor Hosp, AP HP, Paris Est Creteil UPEC Univ Fac, Dept Pathol,INSERM UMR S 955, Creteil, France

[43] CHU Henri Mondor, AP HP, Biol Hematol & Immunol Dept, Creteil, France

[44] Lausanne Univ Hosp, Dept Lab Med & Pathol, Inst Pathol, Lausanne, Switzerland

[45] Lausanne Univ, Lausanne, Switzerland

[46] Univ Hosp Sch Med, Dept Hematol, Hematol Inst, Caen, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165217

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2302 / 2305

页数：4

共 50 条

[31] Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial
Xu, Wei
Liang, Jin-Hua
Wang, Li
Wang, Xiao-Dong
Cui, Guohui
Zhou, Jianfeng
Xu, Jingyan
Wang, Luqun
Liang, Rong
Chen, Bi-yun
Cheng, Jian
Li, Jian-Yong
BLOOD, 2022, 140 : 9484 - 9485
[32] Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study
Stamatoullas, Aspasia
Ghesquieres, Herv
Filliatre, Lauriane Clement
Quittet, Philippe
Morschhauser, Franck
Ribrag, Vincent
Edeline, Veronique
Brice, Pauline
BLOOD, 2019, 134
[33] Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
Ding, Kaiyang
Liu, Hailing
Ma, Jie
Yang, Haiyan
Cao, Lei
Wang, Huihan
Peng, Hongling
Shi, Wei
Zhao, Xiaoli
Wu, Wei
Zhu, Huayuan
Li, Jianyong
Fan, Lei
HAEMATOLOGICA, 2023, 108 (08) : 2146 - 2154
[34] BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T-CELL LYMPHOMA PATIENTS: A PHASE 2 STUDY OF THE FONDAZIONE ITALIANA LINFOMI
Carella, M.
Pellegrini, C.
Corradini, P.
Orsucci, L.
Volpetti, S.
Argnani, L.
Dodero, A.
Stefoni, V.
Zinzani, P. L.
HAEMATOLOGICA, 2021, 106 (10) : 70 - 70
[35] Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study
Stamatoullas, Aspasia
Ghesquieres, Herv
Filliatre, Lauriane Clement
Quittet, Philippe
Morschhauser, Franck
Ribrag, Vincent
Edeline, Veronique
Brice, Pauline
BLOOD, 2019, 134
[36] A Phase 1-2 Study of Brentuximab Vedotin (Bv) and Bendamustine (B) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL)
O'Connor, Owen A.
Kuruvilla, John
Sawas, Ahmed
Deng, Changchun
Patterson, Molly
Connors, Joseph M.
Amengual, Jennifer E.
Crump, Michael
Villa, Diego
BLOOD, 2014, 124 (21)
[37] Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
Voruz, Sophie
de Leval, Laurence
Cairoli, Anne
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
[38] Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30Positive Cutaneous T-Cell Lymphoma
Wang, Qian
Jiang, Ming
Zhang, Chunlei
Wu, Sheng
Jiang, Wenhan
Ji, Meng
Chen, Tong
BLOOD, 2022, 140 : 12044 - 12045
[39] A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
Park, Byeong-Bae
Kim, Won Seog
Suh, Cheolwon
Hong, Jung Yong
Yang, Deok-Hwan
Lee, Won Sik
Do, Young Rok
Koh, Young Il
Won, Jong-Ho
Kim, Min Kyoung
Jo, Jae-Cheol
Hyun, Shin Young
Kim, Jeong-A
Oh, Young Ha
Lee, Seung-Sook
LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3251 - 3257
[40] Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
Sophie Voruz
Laurence de Leval
Anne Cairoli
Experimental Hematology & Oncology, 10

← 1 2 3 4 5 →